tetano
Editor, Senior Moderator
Biochem Biophys Res Commun. 2018 Nov 4. pii: S0006-291X(18)32350-7. doi: 10.1016/j.bbrc.2018.10.166. [Epub ahead of print]
[h=1]Vaccine adjuvant ARNAX promotes mucosal IgA production in influenza HA vaccination.[/h] Takeda Y[SUP]1[/SUP], Takaki H[SUP]1[/SUP], Fukui-Miyazaki A[SUP]1[/SUP], Yoshida S[SUP]1[/SUP], Matsumoto M[SUP]1[/SUP], Seya T[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Adjuvant stimulates pattern-recognition receptors (PRRs) expressed by dendritic cells, which causes immune-enhancing of T lymphocytes. Adjuvant also induces innate immune response in whole-body cells via PRRs to evoke cytokinemia. A cytokine-mediated immune response is important for the systemic protection of a host from microbial infections. Using an influenza subcomponent vaccine in a mouse model, we intranasally administered a TLR3-specific adjuvant ARNAX + HA split vaccine to mice. ARNAX efficiently induced mucosal IgA and systemic IgG production by nasal drop. Moreover, ARNAX + HA simultaneously induced CD8 and CD4 T cell activation. We have previously shown that ARNAX does not induce harmful systemic cytokine production. Thus, our findings indicate that the ARNAX + HA vaccine is a harmless prophylactic vaccine for flu that induces HA-specific T cell activation and IgA/IgG production. These results suggested that ARNAX + antigen enhanced the immune response without inducing inflammatory toxicity for vaccination against infectious diseases.
[h=4]KEYWORDS:[/h] Class-switch recombination; Dendritic cell; IgA production; Influenza A virus; TLR3 agonist; Vaccine adjuvant
PMID: 30404733 DOI: 10.1016/j.bbrc.2018.10.166
[h=1]Vaccine adjuvant ARNAX promotes mucosal IgA production in influenza HA vaccination.[/h] Takeda Y[SUP]1[/SUP], Takaki H[SUP]1[/SUP], Fukui-Miyazaki A[SUP]1[/SUP], Yoshida S[SUP]1[/SUP], Matsumoto M[SUP]1[/SUP], Seya T[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Adjuvant stimulates pattern-recognition receptors (PRRs) expressed by dendritic cells, which causes immune-enhancing of T lymphocytes. Adjuvant also induces innate immune response in whole-body cells via PRRs to evoke cytokinemia. A cytokine-mediated immune response is important for the systemic protection of a host from microbial infections. Using an influenza subcomponent vaccine in a mouse model, we intranasally administered a TLR3-specific adjuvant ARNAX + HA split vaccine to mice. ARNAX efficiently induced mucosal IgA and systemic IgG production by nasal drop. Moreover, ARNAX + HA simultaneously induced CD8 and CD4 T cell activation. We have previously shown that ARNAX does not induce harmful systemic cytokine production. Thus, our findings indicate that the ARNAX + HA vaccine is a harmless prophylactic vaccine for flu that induces HA-specific T cell activation and IgA/IgG production. These results suggested that ARNAX + antigen enhanced the immune response without inducing inflammatory toxicity for vaccination against infectious diseases.
[h=4]KEYWORDS:[/h] Class-switch recombination; Dendritic cell; IgA production; Influenza A virus; TLR3 agonist; Vaccine adjuvant
PMID: 30404733 DOI: 10.1016/j.bbrc.2018.10.166